Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 5/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1544461 | 0.86 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1544334 | 0.86 | USP30 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1544581 | 0.86 | GSK3A (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2896306 | 0.80 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2897435 | 0.78 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5479867 | 0.75 | USP30 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5479857 | 0.75 | USP30 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5485393 | 0.73 | USP30 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1544902 | 0.73 | USP30 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1544344 | 0.73 | GAA (0.48) | MAPTHPGDTSHRTP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1716152-B1 | FUSED HETROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2008-07-30 | — | — | EP | claimed |
| US-20070185095-A1 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | claimed |
| US-20060009443-A1 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-01-12 | — | — | US | claimed |
| EP-2311830-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | AstraZeneca AB (SE) | 2011-04-20 | — | — | EP | disclosed |
| EP-1723144-B1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-7585881-B2 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2009-09-08 | — | — | US | disclosed |
| US-7585881-B2 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2009-09-08 | — | — | US | disclosed |
| US-7585881-B2 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2009-09-08 | — | — | US | disclosed |
| EP-1716152-B1 | FUSED HETROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2008-07-30 | — | — | EP | disclosed |
| US-20080045571-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045571-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20070293545-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
| US-20070293545-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
| US-20070293545-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
| US-20070185095-A1 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| US-20070179188-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | US | disclosed |
| US-20070179188-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | US | disclosed |
| US-20070179188-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | US | disclosed |
| US-20060009443-A1 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-01-12 | — | — | US | disclosed |
| US-20050272779-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185095-A1 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM1, GRM3, GRM5 | PSEN1 1636/4885PSEN2 1692/4885APH1B 3629/4885 |
| US-20070179188-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM5, GRIK5, GRM2 | PSEN1 411/4885PSEN2 319/4885APH1B 1746/4885 |
| US-20050272779-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM5, GRIK5, GRM2 | PSEN1 400/4885PSEN2 310/4885APH1B 1709/4885 |
| US-20060009443-A1 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM3, GRM1, GRM5 | PSEN1 1274/4885PSEN2 1240/4885APH1B 3296/4885 |
| US-20080045571-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | GRM5, GRIK5, GRM2 | PSEN1 400/4885PSEN2 310/4885APH1B 1709/4885 |
| US-20070293545-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | GRM5, GRIK5, GRM2 | PSEN1 400/4885PSEN2 310/4885APH1B 1709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.